# US 2010/0168080 A1 · Novel compounds useful as cc chemokine receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168080 A1
- Document ID: US20100168080A1
- Status: Published application
- Kind: A1
- Application number: 12/639,297
- Filed: 2009-12-16
- Published: 2010-07-01
- Earliest claimed: 2008-12-17
- Inventors: Uttam KHAMRAI; Sumit Kumar Karak; Matthew Ronsheim; Ashis Kumar Saha
- Web page: https://patentgrep.com/patent/US20100168080A1

## CPC

- C07D 267/10: not condensed with other rings
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/445: Non condensed piperidines, e.g. piperocaine
- A61K 31/5375: 1,4-Oxazines, e.g. morpholine
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 3/06: Antihyperlipidemics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D 207/12: Oxygen or sulfur atoms
- C07D 211/48: having an acyclic carbon atom attached in position 4
- C07D 211/54: Sulfur atoms
- C07D 211/62: attached in position 4
- C07D 265/30: not condensed with other rings
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 498/10: Spiro-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel morpholine, oxazapane and piperidine derivatives that act as ligands for CC chemokine receptors, such as CCR1. The invention also relates to methods of preparing the compounds, compositions containing the compounds, and to methods of treatment using the compounds.

## Claims

### Claim 1

A compound having the chemical formula:
wherein
R8 is aryl-X4—, heteroaryl-X4—, aryl, heterocycle or heteroaryl;
X4 is —O—, —S—, —S(O)—, —S(O)2—, —S(O)2NRo— or —NRp, where Ro and Rp are each, independently, hydrogen or alkyl;
Y4 is —C(O)—, —(CH2)2—, —(CH2)3—, —CH2C(O)—, —(CH2)2C(O)—, —C(O)CH2—, —C(O)—(CH2)2— or —CH2CH(OH)CH2—;
R7 is hydrogen or alkyl;
B is —C— or —O—;
R9 is hydrogen, hydroxyl or cyano;
X5 is —O—, —NRe—, —S—, —S(O)— or —S(O)2 where Re is hydrogen or alkyl;
Z7 is aryl, heteroaryl, arylalkyl, heteroarylalkyl;
p is 0 or 1;
q is 0 or 1;
Z4, Z5 and Z6 are each, independently, hydrogen, alkyl, arylalkyl, heteroarylalkyl, -(alkylene)-J-aryl or -(alkylene)-J-heteroaryl, where J is —O— or —NRq— and Rq is hydrogen or alkyl;
provided, however, that when R9 is hydroxyl or cyano, then q is 0, B is —C—, and Z4, Z6 are both alkyl or both hydrogen;
provided, however, that when R9 is H, then q is 1, p is 0, and B is —C—;
provided, however, that when B is —O—, and both R9 and —X5—Z7 are absent; then Z5 is not hydrogen when p is 0;
provided, however, that when B is —O—, R9 and —X5—Z7 are absent and p is 1; then either Z4, Z6 or Z5 are both not hydrogen;
provided, however, that when B is —C—, Z4, Z6 are both hydrogen, and p is 0, then R9 is cyano, q is 0, Z7 is arylalkyl, and Y4 is —(CH2)3—;
wherein, when present, any aryl, heterocycle or heteroaryl group may optionally be substituted by halogen, hydroxy, cyano, nitro, amino, alkylamino, dialkylamino, arylamino, diarylamino, amido, alkylamido, dialkylamido, carboxyl, alkyl, halogenated alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycle, heterocyclealkyl, aroyl, acyl, alkoxy, aryloxy, heteroaryloxy, cycloalkyloxy, cycloalkylalkyloxy, arylalkyloxy, heteroarylalkyloxy, alkythio, arylthio, alkylsulfinyl, alkylsulfonyl, arylsulfinyl, arylsulfonyl, heteroarylsulfinyl, heteroarylsulfonyl, alkoxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, —NRrC(O)Rs, —NRtSO2Ru, where Rpr and Rt are each, independently, hydrogen or alkyl, Rs is amino, aminoalkyl, alkyl or cycloalkyl, and Ru is hydrogen or alkyl; and combinations thereof;
and pharmaceutically acceptable salts or solvates or N-oxides thereof, or solvates of pharmaceutically acceptable salts thereof, or solvates of N-oxides thereof, or isomers, or prodrugs thereof;
with the proviso that said compound is not
1-[2-(4-fluorophenoxy)ethyl]-N-(4-fluorophenyl)-4-piperidinamine,
N-(4-chlorophenyl)-1-[2-(4-fluorophenoxy)ethyl]-4-piperidinamine,
N-(4-chlorophenyl)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinamine,
N-(4-chlorophenyl)-1-(3-phenoxypropyl-4-piperidinamine,
N-(4-fluoro-2-methylphenyl)-1-[3-(4-fluorophenoxy)propyl]-4-piperidinamine,
1-[3-(4-fluorophenoxy)propyl]-N-(4-fluorophenyl)-N-methyl-4-piperidinamine,
1-[3-(4-fluorophenoxy)propyl]-N-(4-fluorophenyl)-4-piperidinamine,
N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-phenylsulfanyl)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzenesulfonyl)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-phenoxy)-piperidin-1-yl]-2-hydroxy-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-cyano-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, selected from:
(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[4-(4-fluoro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-cyano-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-urea,
1-[3-(4-Chloro-2-isoxazol-5-yl-phenoxy)-propyl]-4-(4-fluoro-benzyl)-3,3-dimethyl-piperidin-4-ol,
4-(4-Chloro-benzyl)-1-[3-(4-chloro-2-isoxazol-5-yl-phenoxy)-propyl]-3,3-dimethyl-piperidin-4-ol,
1-[3-(5-Chloro-benzoimidazol-1-yl)-propyl]-4-(4-chloro-benzyl)-3,3-dimethyl-piperidin-4-ol,
1-[2-(5-Chloro-benzoimidazol-1-yl)-ethyl]-4-(4-chloro-benzyl)-3,3-dimethyl-piperidin-4-ol,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-2-dimethylamino-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-isobutyramide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-2,2-dimethyl-propionamide,
Cyclobutanecarboxylic acid (5-chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-amide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-methanesulfonamide,
5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-benzoic acid,
5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-benzamide,
1-[3-(5-Chloro-benzoimidazol-1-yl)-propyl]-4-(4-chloro-phenyl)-3,3-dimethyl-piperidin-4-ol,
1-[3-(5-Chloro-benzoimidazol-1-yl)-propyl]-4-(4-fluoro-benzyl)-piperidine-4-carbonitrile,
N-(5-Chloro-2-{3-[4-(3,4-difluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-3-methoxy-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-acetamide,
5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-N,N-dimethyl-benzamide,
5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-N-methyl-benzamide,
1-[2-(6-Chloro-1H-benzoimidazol-2-yl)-ethyl]-4-(4-chloro-benzyl)-3,3-dimethyl-piperidin-4-ol,
N-(5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
4-(4-Chloro-benzyl)-1-[3-(4-chloro-2-pyrazol-1-yl-phenoxy)-propyl]-3,3-dimethyl-piperidin-4-ol,
(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-urea,
(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-urea,
(5-Chloro-2-{2-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{2-[(2R,5R)-2-(4-fluoro-phenoxymethyl)-5-methyl-morpholin-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{2-[(2S,5R)-2-(4-fluoro-phenoxymethyl)-5-methyl-morpholin-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
[5-Chloro-2-(2-{(2S,5R)-2-[2-(4-fluoro-phenyl)-ethyl]-5-methyl-morpholin-4-yl}-2-oxo-ethoxy)-phenyl]-urea,
5-Chloro-2-(2-{(2R,5R)-2-[2-(4-fluoro-phenyl)-ethyl]-5-methyl-morpholin-4-yl)-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{3-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[(2S,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{2-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethoxy}-phenyl)-urea,
1-[(2R,5S)-2-(4-Fluoro-benzyl)-5-methyl-morpholin-4-yl]-2-(4-fluoro-phenoxy)-ethanone,
2-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethanone,
2-[(R)-4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethanone,
2-[(S)-4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethanone,
4-(4-Chloro-phenyl)-1-{2-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
(S)-4-(4-Chloro-phenyl)-1-{2-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
(R)-4-(4-Chloro-phenyl)-1-{2-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
5-Chloro-2-{3-[(2R,5S)-2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{2-[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{2-[2-(4-fluoro-phenoxymethyl)-5-methyl-morpholin-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
[5-Chloro-2-(2-{2-[2-(4-fluoro-phenyl)-ethyl]-5-methyl-morpholin-4-yl}-2-oxo-ethoxy)-phenyl]-urea,
(5-Chloro-2-{3-[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{2-[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethoxy}-phenyl)-urea,
1-[2-(4-Fluoro-benzyl)-5-methyl-morpholin-4-yl]-2-(4-fluoro-phenoxy)-ethanone,
2-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-ethanone,
[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-propan-1-one-3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidine],
5-Chloro-2-{3-[2-(4-fluoro-benzyl)-5-methyl-morpholin-4-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{2-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-phenyl)-urea,
3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propan-1-one,
3-[(S)-4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propan-1-one,
3-[(R)-4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propan-1-one,
4-(4-Chloro-phenyl)-1-{2-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
(S)-4-(4-Chloro-phenyl)-1-{2-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
(R)-4-(4-Chloro-phenyl)-1-{2-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
(5-Chloro-2-{2-[7-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-oxo-ethoxy}-phenyl)-urea,
(5-Chloro-2-{3-[7-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[7-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{2-[7-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethoxy}-phenyl)-urea,
4-[3-(4-Chloro-phenoxy)-propyl]-2-(4-fluoro-benzyl)-[1,4]oxazepane,
(5-Chloro-2-{2-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethoxy}-phenyl)-urea,
3-[2-(4-Fluoro-benzyl)-[1,4]oxazepan-4-yl]-N-(3-fluoro-phenyl)-propionamide,
N-(3-Chloro-phenyl)-3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propionamide,
N-(5-Chloro-2-methoxy-phenyl)-3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propionamide,
(5-Chloro-2-{3-[2-(3,4-difluoro-benzyl)-[1,4]oxazepan-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[2-(3,4-difluoro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[2-(3-fluoro-benzyl)-[1,4]oxazepan-4-yl]-3-oxo-propoxy}-phenyl)-urea,
(5-Chloro-2-{3-[2(3-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-phenyl)-urea,
2,6-Dichloro-N-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propyl}-benzenesulfonamide,
4-[3-(2-Bromo-4-chloro-phenoxy)-propyl]-2-(4-fluoro-benzyl)-[1,4]oxazepane,
5-chloro-2-{(R)-3-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-hydroxy-propoxy}-benzamide,
5-chloro-2-{(S)-3-[(R)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-hydroxy-propoxy}-benzamide,
5-chloro-2-{(R)-3-[(S)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-hydroxy-propoxy}-benzamide,
5-chloro-2-{(S)-3-[(S)-2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-hydroxy-propoxy}-benzamide,
N-(3-Chloro-2-methyl-phenyl)-2-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-acetamide,
4-[3-(2,6-Dichloro-phenoxy)-propyl]-2-(4-fluoro-benzyl)-[1,4]oxazepane,
2,6-Dichloro-N-{2-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethyl}-benzenesulfonamide,
N-{3-[2-(4-Fluoro-benzyl)-[1,4]oxazepan-4-yl]-propyl}-4-methoxy-benzenesulfonamide,
4-Chloro-N-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propyl}-benzenesulfonamide,
5-Chloro-2-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-benzoic acid,
(5-Chloro-2-{3-[2-(4-chloro-benzyl)-[1,4]oxazepan-4-yl]-propoxy}-phenyl)-urea,
2-(4-Chloro-2-isoxazol-5-yl-phenoxy)-1-[7-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethanone,
3-[4-(4-Chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-1-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-propan-1-one,
4-(4-Chloro-phenyl)-1-{2-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-ethyl}-3,3-dimethyl-piperidin-4-ol,
4-chloro-2-{3-[2-(4-fluoro-benzyl)-[1,4]oxazepan-4-yl]-2-hydroxy-propoxy}-benzamide,
N-(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-isopropoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-isopropoxy-phenyl)-acetamide,
N-(2-{3-[4-(4-Chloro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-isopropoxy-phenyl)-acetamide,
N-(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-4-methoxy-phenyl)-acetamide,
(5-Chloro-2-{2-[4-(4-fluoro-phenoxy)-piperidin-1-yl]-2-oxo-ethoxy}-phenyl)-urea,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-2-hydroxy-propoxy}-4-methoxy-benzoic acid,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-2-hydroxy-propoxy}-4-methoxy-N-methyl-benzamide,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-N-methyl-benzamide,
5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-benzoic acid methyl ester,
(5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-pyrrolidin-1-yl-methanone,
5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-N-methyl-benzamide,
(5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-phenyl)-pyrrolidin-1-yl-methanone,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-benzoic acid,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-hydroxy-N-methyl-benzamide,
5-Chloro-2-{3-[4-(4-chloro-phenyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-4-methoxy-N,N-dimethyl-benzamide,
5-Chloro-4-dimethylamino-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-N-methyl-benzamide,
5-Chloro-2-{3-[4-(4-fluoro-benzyl)-4-hydroxy-3,3-dimethyl-piperidin-1-yl]-propoxy}-N-methyl-4-methylamino-benzamide,
and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof.

### Claim 3

A compound chosen from:
5-Chloro-2-{3-[3-(4-chloro-phenyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-N-methyl-benzamide,
5-Chloro-2-{3-[3-(4-chloro-benzyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-N-methyl-benzamide,
N-[5-Chloro-2-(2-{[1-(4-fluoro-benzyl)-4-hydroxy-piperidin-4-ylmethyl]-amino}-ethoxy)-4-methoxy-phenyl]-acetamide,
5-Chloro-2-(2-{[1-(4-fluoro-benzyl)-4-hydroxy-piperidin-4-ylmethyl]-amino}-ethoxy)-4-methoxy-N-methyl-benzamide,
N-(5-Chloro-2-{3-[3-(4-chloro-phenyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-(5-Chloro-2-{3-[3-(4-chloro-benzyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
N-[5-Chloro-2-(2-{[1-(4-chloro-benzyl)-4-hydroxy-piperidin-4-ylmethyl]-amino}-ethoxy)-4-methoxy-phenyl]-acetamide,
5-Chloro-2-{3-[3-(4-fluoro-benzyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-N-methyl-benzamide,
N-(5-Chloro-2-{3-[3-(4-fluoro-benzyl)-3-hydroxy-pyrrolidin-1-yl]-propoxy}-4-methoxy-phenyl)-acetamide,
5-Chloro-2-{2-[1-(4-chloro-benzyl)-4-hydroxy-piperidin-4-ylmethyl]-amino}-ethoxy)-4-methoxy-N-methyl-benzamide,
5-Chloro-2-{2-[8-(4-fluoro-benzyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl]ethoxy}-4-methoxy-N-methyl-benzamide,
5-Chloro-2-[4-(4-fluoro-benzyl)-[1,4]oxazepan-2-ylmethoxy]-4-methoxy-N-methyl-benzamide,
and pharmaceutically acceptable salts thereof, solvates thereof, and solvates of pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

A method for treating a condition that responds to a CC chemokine receptor ligand comprising administering to a patient in need thereof an effective amount of a composition according to claim 4.

### Claim 6 (depends on 5)

The method of claim 5, wherein the CC chemokine receptor ligand is a CCR1 antagonist.

### Claim 7 (depends on 5)

The method according to claim 5, wherein the condition is an inflammatory disorder or obesity.

### Claim 8 (depends on 7)

The method according to claim 7, wherein the condition is obesity.
